# Theranexus

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/theranexus

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.theranexus.com
- Total disclosed funding: $3.1M
- Latest round: Series A (Dec 16, 2014)
- Investors on record: 4

## About

Theranexus is a biopharmaceutical company focused on developing novel therapies for rare neurological diseases, leveraging its innovative platform to identify and characterize therapeutic candidates.Theranexus was founded in 2014 in Lyon, France, and specializes in the treatment of rare neurological disorders. The company has completed 2 deals to date, with its most recent funding round being a PIPE on September 15, 2020, raising EUR 2.245 million from Auriga Partners, Financière Arbevel, and other investors. The firm was founded by Mathieu Charvériat, who has a background in launching biopharmaceutical ventures.Theranexus specializes in innovative treatment solutions for rare neurological diseases, with its lead clinical candidate targeting Batten disease, a severe neurodegenerative disorder. The end users of its products include healthcare professionals, institutions specializing in neurology, and patients. Its market focus spans Europe and North America, addressing the significant needs in these regions for effective therapeutic options.In the most recent fiscal year, Theranexus generated a revenue of EUR 0, while reporting an EBITDA of EUR -6,243,904.9 for 2022. The company’s revenue model likely involves partnerships and collaborations with healthcare institutions and pharmaceutical companies, which may include milestone payments and royalties based on the successful development and commercialization of its therapeutic products.Theranexus plans to utilize the EUR 2.245 million raised in September 2020 to support the development of its therapeutic candidates and expand its clinical trials. The company is focusing on introducing new products to address rare neurological conditions, including Batten disease, while also exploring opportunities for expansion into new markets across Europe and North America.

## Funding rounds

- Series A, Dec 16, 2014, $3.1M — Auriga Partners, Sofimac Partners, CEA Investissement, Rhone-Alpes Creation

## Investors

- Auriga Partners (https://capitalatlas.ai/funds/auriga-partners) — Series A
- Sofimac Partners (https://capitalatlas.ai/funds/sofimac-partners) — Series A
- CEA Investissement (https://capitalatlas.ai/funds/cea-investissement) — Series A
- Rhone-Alpes Creation (https://capitalatlas.ai/funds/rhone-alpes-creation) — Series A